Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Spatial-temporal tracking of Brca1-driven breast tumorigenesis from sporadic mutant cells with a genetic mosaic mouse model

ABSTRACT: We utilized a genetic tool termed Mosaic Analysis with Double Markers (MADM) to achieve a sporadic loss of heterozygosity of Brca1 & Trp53 in mouse mammary epithelial cells and concomitantly label them with GFP. This MADM-based mouse model initiated cancer with sparse GFP+ mutant cells and developed mammary tumors that resemble human disease at pathological, transcriptomic, and genomic levels. This dataset provides bulk RNA sequencing of twelve mammary tumors from MADM Brca1-Trp53 animals.

ORGANISM(S): Mus musculus

PROVIDER: GSE214433 | GEO | 2023/10/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

RNAseq data for mouse mammary tumors from three novel genetically engineered mouse models combining loss of Brca1, p53 and Rb supression

Project description:We have developed novel genetically engineered mouse mammary cancer models that develop hormone receptor-positive or -negative tumors depending on the combination of genetic abrrations induced in tumors. Tumors with loss of Brca1 and Trp53 are hormone receptor (HR) negative and tumors with or without Brca1 loss together with concomitant loss of Trp53 and inhibition of proteins of Rb family (Rbf) are HR positive. Transcriptome analysis revealed that HR-positive and -negative mammary tumors recapitulated human luminal and basal-like breast cancer expression signatures, respectively, confirming the histology-defined subtypes.

2022-11-04 | GSE206068 | GEO

Single cell RNA-Seq data for Trp53/Brca1-null premalignant mammary epithelial cells and tumor cells with a K8+ luminal origin

Project description:BRCA1 mutation-carriers are predisposed to develop Basal-like breast cancer (BLBC), and p53 mutations are present in the majority of human BLBC cases, suggesting loss of these two tumor suppressors play key roles in development of BLBC. Recent studies suggest that the majority of human breast cancers, including BLBC, may originate from mammary epithelial cells (MECs) in the luminal lineage. However, how loss of p53 and BRCA1 contributes to development of BLBC from luminal MECs remains largely elusive. We developed a novel genetic targeting and lineage tracing approach based on intraductal injection of Cre-expressing adenovirus under the control of the pan-luminal Keratin 8 (K8) promoter (Ad-K8-Cre). We performed intraductal injection of Ad-K8-Cre to female mice carrying conditional knockout alleles of Brca1 (Brca1L) and Trp53 (Trp53L). The injected females developed mammary tumors similar to human BLBC within 12 months after injection. Here we characterized MECs targeted by Ad-K8-Cre at different time points after the intraductal injection, as well as mammary tumors developed in this model, by single cell expression analysis.

2019-06-27 | GSE130453 | GEO

Microarray expression profiling data for Trp53/Brca1-null mammary tumors derived from K8+ luminal cells

Project description:BRCA1 mutation-carriers are predisposed to develop Basal-like breast cancer (BLBC), and p53 mutations are present in the majority of human BLBC cases, suggesting loss of these two tumor suppressors play key roles in development of BLBC. Recent studies suggest that the majority of human breast cancers, including BLBC, may originate from mammary epithelial cells (MECs) in the luminal lineage. However, how loss of p53 and BRCA1 contributes to development of BLBC from luminal MECs remains largely elusive. We developed a novel genetic targeting and lineage tracing approach based on intraductal injection of Cre-expressing adenovirus under the control of the pan-luminal Keratin 8 (K8) promoter (Ad-K8-Cre). We performed intraductal injection of Ad-K8-Cre to female mice carrying conditional knockout alleles of Brca1 and Trp53. The injected females developed mammary tumors within 12 months after injection. Microarray expression profiling of these tumors showed that they most closely resembled human BLBC.

2019-06-27 | GSE114787 | GEO

RNA-Seq data for Trp53/Brca1-null premalignant mammary epithelial cells with a K8+ luminal origin

2019-06-27 | GSE126761 | GEO

Microarray expression profiling data for Trp53/Brca1-null mammary tumors derived from K8+ luminal cells

Project description:Microarray expression profiling data for Trp53/Brca1-null mammary tumors derived from K8+ luminal cells

| PRJNA472622 | ENA

Dropseq to study heterogeneity and tumorigenesis of Brca1-deficient mouse mammary tumors.

Project description:Brca1 mutation predisposes women to early onset of breast and ovarian cancers.Through its diverse functions in DNA damage repair, cell cycle control, transcription regulation, ubiquitination and so on, BRCA1 acts as a very significant tumor suppressor and genomic safeguard. Brca1 deficiency induces severe cellular stress, when occurring in the mammary glands, it impairs the regular developmental process and eventually causes tumorigenesis due to accumulation of genome instability and other mechanisms. The Brca1-defiencient mouse mammary tumor were characterized with great tumoral heterogeneity, which is in line with the human breast cancers carrying BRCA1 mutations. Here we studied the molecular complexicity of Brca1-deficient mouse mammary tumors vie Dropseq.

2021-11-17 | GSE148566 | GEO

RNAseq of Brca1-deficient mouse mammary tumors

2021-11-17 | GSE148565 | GEO

Single cell RNA-seq to study heterogeneity and tumorigenesis of Brca1-deficient mouse mammary tumors.

2021-11-17 | GSE148569 | GEO

RNAseq of Brca1-deficient mouse mammary tumors

Project description:RNAseq of Brca1-deficient mouse mammary tumors

| PRJNA625044 | ENA

A BRCA1 coiled-coil domain variant disrupting PALB2 interaction predisposes to mammary tumors with a targetable defect in homologous recombination repair [CNV-seq]

Project description:The BRCA1 tumor suppressor gene encodes a multi-domain protein for which several functions have been described. These include a key role in homologous recombination repair (HRR) of DNA double-strand breaks (DSBs), which is shared with two other high-risk hereditary breast cancer suppressors, BRCA2 and PALB2. Although both BRCA1 and BRCA2 interact with PALB2, BRCA1 missense variants affecting its PALB2-interacting coiled-coil domain are considered sequence variants of uncertain clinical significance (VUS). Using genetically engineered mice, we now show that a BRCA1 coiled-coil domain VUS, Brca1 p.L1363P, disrupting the interaction with PALB2 leads to embryonic lethality and loss of breast cancer suppression. Brca1 p.L1363P mammary tumors develop with a similar latency as Brca1-null tumors, but show different histopathological features and more stable DNA copy number profiles. Nevertheless, Brca1 p.L1363P mammary tumors are HRR-incompetent and responsive to cisplatin and PARP inhibition.

2022-02-01 | GSE182449 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data